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hanging epidemiology and treatment options in invasive can-
ida infections
. Gottlieb
Concord Hospital, Concord, Australia
There is changing epidemiology and diversity of invasive fungal
nfections, including those causing invasive candidiasis. Determi-
ants for this varied epidemiology include geographical location
there are global, hospital and unit differences in epidemiology;
atient risk factors – eg. ICU, bone marrow or solid organ trans-
lantation; central line and TPN use; use of antifungal prophylaxis
nd prior broad-spectrum antibiotic use. Continuing surveillance
f trends is key to early understanding of new changes and limi-
ations for treatment. One of the drivers for this increased interest
n the epidemiology and susceptibility of invasive Candida infec-
ions are newly available options in antifungal therapy – newer
riazoles (eg. voriconazole and posaconazole), lipid formulations
f amphotericin B and three echinocandin drugs - caspofungin,
nidulafungin and micafungin. With extra options, the approach to
herapy has also evolved, with increasing tendency to pre-emptive
se of antifungals to reduce morbidity in high risk patients, as
ell as, depending on patient group, both directed and empiric
herapy. Along with increased choices in therapy, there is now
eed for recognition of species speciﬁc limitations – for triazoles
C.glabrata, C.krusei), echinocandins (C.parapsilosis), amphotericin
(C.lusitaniae) are examples of potentially problematic species.
he detection of resistant Candida species provides parallels to
election of more inherently resistant strains by antibiotic ther-
py in bacteria. Reﬁnement of in-vitro susceptibility breakpoints
urrently underway by EUCAST and CLSI, will aid in treatment
election, but will also provide more complexity. Increasing use
f antifungals in high risk patient groups, and the need to guide
ppropriate options and duration for antifungal therapy will
equire the development, and regular updating of more sophis-
icated guideline algorithms, such as the 2009 IDSA guidelines
http://cid.oxfordjournals.org/content/48/5/503.1.full. Such guide-
ines will continue to need to take into account not only the
nfecting species, but patient factors such as the underlying dis-
ase, presence of a removable focus, potential drug interactions
nd prior antifungal use.
ttp://dx.doi.org/10.1016/j.ijid.2012.05.043nfectious Diseases 16S (2012) e2–e157 e17
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Cryptococcus infection in immunocompetent individuals
G. Reid
University of Illinois, Chicago, IL, USA
Cryptococcus is a signiﬁcant cause of morbidity and mortality
worldwide. It is historically considered an opportunistic infection
associated with meningitis in severely immunocompromised indi-
viduals, such as thosewith Acquired ImmuneDeﬁciency Syndrome
and solid organ transplantation. There are numerous reports, how-
ever, of cryptococcus infection in individuals without any history
of immunocompromise.
Timingandpresentationof infection in immunocompetent indi-
viduals can differmarkedly from that in the immunocompromised,
oftenwithmore subtle symptoms,making diagnosismore difﬁcult.
Work up of these patients can often reveal subclinical immunode-
ﬁciencies in some, but not all.
Even in presumably immunocompetent individuals cryptococ-
cal meningitis can be fatal if left untreated. In addition, patient
response to various therapies varies based on risk factor for
infection. This has lead to recommendations for management of
cryptococcal infectionbasedonpatient type–HIV, organ transplant
or nonHIV/nontransplant.
It is important to suspect cryptococcal infection even in
immunocompetent individuals with nonspeciﬁc or intermittent
neurological ﬁndings with no clear etiology. Additionally, work up
of possible immunodeﬁciency is advisable.
http://dx.doi.org/10.1016/j.ijid.2012.05.044
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Meningococcal disease: A public health concern
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